Clinuvel Pharmaceuticals Limited (CUVL)

NASDAQ: CUVL · Real-Time Price · USD

4.910

-0.160 (-3.16%)

At close: Nov 2, 2026, 4:00 PM EST

4.910

0.00 (0.00%)

After-hours: Nov 2, 2026, 4:10 PM EST

Clinuvel Pharmaceuticals Financials Overview

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Revenue	94.02	94.02	95.02	88.18	78.32	65.72
Revenue Growth	-2.37%	-1.04%	7.76%	12.58%	19.17%	36.02%
Gross Profit	78.21	78.21	80.2	80.45	70.8	56.47
Operating Income	40.53	40.53	41.27	48.57	44.13	35.55
Net Income	33.92	33.92	36.17	35.64	30.6	20.88
Earnings Per Share	0.67	0.67	0.72	0.70	0.59	0.40
EPS Growth	3.78%	-6.96%	2.86%	18.11%	46.65%	-16.74%

Fiscal Year	TTM	FY 2026	FY 2025
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025
Ireland	52.51	52.51	46.21
United States	40.73	40.73	47.91
Rest of The World	0.79	0.79	0.9
Total	94.02	94.02	95.02

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Cash & Investments	252.06	252.06	224.11	183.87	156.81	121.51
Total Debt	1.94	1.94	0.53	0.88	1	1.26
Net Cash (Debt)	250.12	250.12	223.58	182.99	155.81	120.25
Net Cash Growth	7.50%	11.87%	22.18%	17.44%	29.57%	47.75%
Net Cash Per Share	4.93	4.93	4.44	3.59	3.01	2.32

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Operating Cash Flow	36.91	36.91	41.1	37.05	36.91	39.87
Capital Expenditures	-1.6	-1.6	-0.3	-5.58	-1.03	-0.43
Free Cash Flow	35.31	35.31	40.8	31.48	35.88	39.44
Free Cash Flow Growth	-11.90%	-13.46%	29.61%	-12.28%	-9.01%	114.25%

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Gross Margin	83.18%	83.18%	84.41%	91.23%	90.40%	85.92%
Operating Margin	43.11%	43.11%	43.43%	55.08%	56.34%	54.09%
Pretax Margin	50.69%	50.69%	54.26%	57.47%	58.19%	52.22%
Profit Margin	36.07%	36.07%	38.07%	40.41%	39.08%	31.77%
FCF Margin	37.55%	37.55%	42.94%	35.70%	45.82%	60.01%

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '26 Nov 2, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Dividend Per Share	0.028	0.050	0.050	0.050	0.050	0.040
Dividend Per Share Growth	7.89%	0%	0%	0%	25.00%	60.00%
Dividend Yield	0.58%	0.49%	0.48%	0.33%	0.28%	0.27%

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '26 Nov 2, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
PE Ratio	10.50	15.28	14.38	21.60	28.87	35.14
P/FCF Ratio	10.24	14.68	12.75	24.46	24.62	18.61
PS Ratio	3.89	5.51	5.48	8.73	11.28	11.16